10-K: Palatin Technologies Faces Delisting Amidst Losses, Advances Pipeline

Palatin Technologies reported a $17.3 million net loss for fiscal year 2025, faces delisting from NYSE American, but secured a significant collaboration with Boehringer Ingelheim and advanced multiple drug candidates.

Summary

• Reported a net loss of $17.3 million for the fiscal year ended June 30, 2025, an improvement from $29.7 million in fiscal year 2024.
• Accumulated deficit reached $459.1 million as of June 30, 2025.
• Cash and cash equivalents stood at $2.6 million, with current liabilities of $8.0 million as of June 30, 2025.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern for one year from the financial statements' issuance date.
• Entered into a Research Collaboration, License and Patent Assignment Agreement with Boehringer Ingelheim in August 2025 for retinal diseases, receiving an upfront payment of $2.3 million (September 2025) and potential for up to $328.2 million in milestones and royalties.
• Achieved a research milestone under the Boehringer Ingelheim collaboration on September 22, 2025, triggering a $6.5 million payment (expected October 2025).
• Vyleesi, previously sold to Cosette in December 2023, resulted in a $3.13 million gain on sale and a $2.12 million gain on purchase commitments in fiscal 2025 due to a settlement agreement.
• Positive topline data reported for Bremelanotide co-administration with tirzepatide (GLP-1 agonist) for obesity in Q1 2025 (Phase 2).
• PL9643 for dry eye disease completed a Phase 3 trial with positive, statistically significant results for the co-primary symptom endpoint of pain (p<0.025).
• Positive topline data reported for oral PL8177 for ulcerative colitis in Q1 2025 (Phase 2 proof-of-concept).
• Positive topline data reported for an MC4R agonist for diabetic nephropathy in Q4 2024 (Phase 2 proof-of-concept).
• Common stock was suspended from trading on NYSE American on May 7, 2025, and now trades on the OTCQB Venture Market under PTNT. NYSE American affirmed delisting on July 7, 2025.
• A 1-for-50 reverse stock split was effective on August 11, 2025.
• Facing a lawsuit from H.C. Wainwright & Co., LLC for breach of contract, seeking monetary damages and warrants.

Sentiment

Score: 3

Explanation: The company is in a critical financial state with a substantial accumulated deficit, ongoing net losses, and a 'going concern' warning. The delisting from NYSE American is a major negative event. While there are positive clinical trial results and a significant collaboration with Boehringer Ingelheim, these are future-oriented and do not immediately resolve the severe liquidity and funding challenges. The need for substantial additional capital is paramount for continued operations.

Positives

• Net loss significantly decreased to $17.3 million in FY2025 from $29.7 million in FY2024.
• Secured a major collaboration with Boehringer Ingelheim for retinal diseases, including an upfront payment of $2.3 million and potential for up to $328.2 million in milestones and royalties.
• Achieved a research milestone under the Boehringer Ingelheim collaboration, triggering an additional $6.5 million payment.
• Reported positive topline data for Bremelanotide co-administered with tirzepatide for obesity in a Phase 2 study.
• PL9643 for dry eye disease successfully completed a Phase 3 clinical trial, demonstrating clinically meaningful and statistically significant results for the co-primary symptom endpoint of pain (p<0.025).
• Positive topline data from a Phase 2 proof-of-concept trial for oral PL8177 in ulcerative colitis.
• Positive topline data from a Phase 2 proof-of-concept study for an MC4R agonist for diabetic nephropathy.
• Realized a gain of $3.13 million on the sale of Vyleesi and a $2.12 million gain on purchase commitments in fiscal 2025.

Negatives

• Reported a substantial net loss of $17.3 million for fiscal year 2025.
• Accumulated deficit of $459.1 million as of June 30, 2025.
• Cash and cash equivalents of $2.6 million as of June 30, 2025, are significantly lower than current liabilities of $8.0 million.
• Management has identified substantial doubt about the company's ability to continue as a going concern for the next year.
• Common stock was suspended from trading on NYSE American and faces delisting, now trading on the OTCQB Venture Market, which may reduce liquidity and market quotations.
• The company will need significant additional funding to complete clinical trials and development of product candidates.
• The commercial success of Vyleesi by Cosette and peptides assigned to Boehringer Ingelheim is uncertain, and significant milestone payments may not be received.
• Facing a lawsuit from H.C. Wainwright & Co., LLC for breach of contract.
• Stockholders may experience dilution from the conversion of preferred stock, exercise of outstanding options and warrants, and vesting of restricted stock units (838,142 shares underlying dilutive securities).
• The company has a limited operating history upon which to base an investment decision for its current product candidates.

Risks

• Substantial doubt about the ability to continue as a going concern due to significant operating losses and need for additional financing.
• Expectation to incur substantial net losses for the foreseeable future and may never achieve or maintain profitability.
• Need for additional funding to complete clinical trials, which may not be available on acceptable terms or at all.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights.
• Product candidates are in early stages of development and subject to clinical testing and regulatory approval; failure to successfully develop and test them would lead to failure.
• Prolonged or delayed clinical trials could prevent timely commercialization, incur additional costs, and delay revenue.
• Even if product candidates receive regulatory approval, they may not achieve market acceptance.
• Emergence of side effects could require additional clinical trials, labeling changes, or market withdrawal, hindering revenue generation.
• Product candidates are subject to ongoing regulatory requirements, and non-compliance could lead to sanctions or suspension of sales.
• Stock price is volatile and may fluctuate disproportionately to operating performance, limiting investors' ability to sell at a profit.
• Delisting from NYSE American could lead to limited market quotations, reduced liquidity, limited news coverage, and decreased ability to raise financing.
• Reliance on third parties for preclinical studies, clinical trials, and manufacturing, over whom there is limited control, could harm product development.
• Internal computer systems or those of third-party contractors may fail or suffer security breaches, disrupting product development programs.
• Challenges with properly managing the use of artificial intelligence (AI) and uncertainty regarding its legal landscape could result in reputational harm, competitive harm, and legal liability.
• Potential claims that employees, consultants, or contractors have wrongfully used or disclosed confidential information of third parties.
• Subject to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws; non-compliance could lead to substantial penalties.
• High dependence on management team, senior staff, and third-party contractors; loss of their services could adversely affect the business.
• Inability to keep up with rapid technological change in the biotechnology and pharmaceutical industries could render future approved products obsolete.
• Competing products and technologies may make proposed products noncompetitive.
• Inability to establish sales and marketing capabilities or maintain agreements with third parties could prevent revenue generation.
• Inability to obtain adequate reimbursement from private insurers and other healthcare payers for products.
• Substantial liabilities from product liability lawsuits could limit commercialization.
• Inability to protect intellectual property rights or secure rights to patents of others would diminish the value of intellectual property.
• Infringement or alleged infringement of third-party intellectual property rights could harm the business.
• Patent applications and enforcement/defense of issued patents may be impacted by changes in U.S. and foreign standards.
• Inability to protect intellectual property rights throughout the world, especially in countries with weaker IP laws.
• Failure to keep trade secrets confidential could allow competitors to use technologies.
• Legislative or regulatory healthcare reforms may make it more difficult and costly to obtain approvals and market products.
• Changes in healthcare policy could adversely affect the business, including price controls and reimbursement pressures.

Future Outlook

The company expects to incur significant losses for the foreseeable future and may never achieve or maintain profitability. It anticipates needing additional funding beyond existing cash and the Boehringer Ingelheim payments to complete planned clinical trials and development programs, and to submit regulatory applications. The company is evaluating strategies including equity financing, debt, or expense reductions. Existing cash and cash equivalents are expected to fund operations through the second half of calendar year 2025.

Management Comments

• Our management has determined that there is substantial doubt about our ability to continue as a going concern because of our need to raise significant additional financing to complete clinical trials and development of our product candidates.
• We expect to incur significant expenses as we continue our development of MC1R and MCR products.
• We do not anticipate receiving significant milestone payments for at least the next year from the issuance of this Annual Report and may never receive significant milestone payments [from Cosette for Vyleesi].
• We intend to focus future efforts on our bremelanotide combination products MC1R product candidates, primarily for ocular indications.
• We are evaluating strategies to obtain additional funding for future operations which include but are not limited to obtaining equity financing, issuing debt, or reducing planned expenses.
• A failure to raise additional funding or to effectively implement cost reductions could harm our business, results of operations, and future prospects.
• If the Company is not able to secure adequate additional funding in future periods, the Company would be forced to make additional reductions in certain expenditures. This may include liquidating assets and suspending or curtailing planned programs.
• We may also have to delay, reduce the scope of, suspend, or eliminate one or more research and development programs or its commercialization efforts or pursue a strategic transaction.
• If the Company is unable to raise capital when needed or enter into a strategic transaction, then the Company may be required to cease operations, which could cause its stockholders to lose all or part of their investment.
• Based on our current operating and development plans, we expect that our existing cash and cash equivalents as of the date of this filing will be sufficient to fund currently anticipated operating expenses through the second half of calendar year 2025.

Industry Context

The biopharmaceutical industry is characterized by extensive research, rapid technological change, and intense competition from companies with significantly greater resources. The obesity and diabetes markets, in particular, have seen increased competition with the extensive use of GLP-1 receptor agonists like Wegovy and Ozempic. The dry eye disease and inflammatory bowel disease markets are also highly competitive with numerous marketed products and late-stage clinical candidates. Palatin's strategy involves developing first-in-class medicines based on the melanocortin receptor system and forming marketing collaborations with industry leaders. The company faces the challenge of competing against established products and new technologies while navigating complex regulatory landscapes and the need for substantial funding for its early-stage pipeline.

Comparison to Industry Standards

• The company competes with major pharmaceutical and biotechnology companies like Novo Nordisk, Sanofi, Merck, Eli Lilly, Roche, Pfizer, Regeneron, and Altimmune in the obesity and diabetes markets, which have significantly greater financial, technological, manufacturing, and distribution resources.
• In the obesity market, existing melanocortin agonists like Imcivree (setmelanotide) by Rhythm Pharmaceuticals are already marketed for specific monogenic or syndromic obesity. Rhythm Pharmaceuticals also has Bivamelagon in Phase 2 for hypothalamic obesity.
• For dry eye disease, current treatments include artificial tears, immunosuppressants like Restasis (Allergan) and Xiidra (Novartis), and numerous drugs in clinical development (e.g., perfluorohexyloctane, cyclosporine, TRPM8 selective agonist). No other reported MC1R agonist drugs are in clinical trials by third parties for dry eye disease, suggesting a potentially unique mechanism for PL9643.
• For ulcerative colitis, FDA-approved drugs include aminosalicylates, immunosuppressants, corticosteroids, and biologics like infliximab and adalimumab. Many other drugs are in development (e.g., Janus kinase inhibitors, monoclonal antibodies, S1P1 receptor modulators). No other reported MC1R agonist drugs are in clinical trials for inflammatory bowel diseases, indicating a novel approach for PL8177.
• The company's reliance on contract manufacturers for GMP-compliant production is a common industry practice for smaller biopharmaceutical firms, but it introduces dependence on third-party compliance and capacity.

Management Changes

Corporate Governance

Legal Proceedings

• H.C. Wainwright & Co., LLC v. Palatin Technologies, Inc., Case No: 650878/2025, filed February 13, 2025, in the Supreme Court of the State of New York, County of New York.
• Wainwright asserts three causes of action for breach of contract, seeking monetary damages and the award of warrants allegedly due under an engagement agreement from January 29, 2024.
• Palatin filed its answer on March 20, 2025, denying all liability and asserting several affirmative defenses, planning to vigorously defend the lawsuit.
• Management believes a loss is reasonably possible but not probable, and is unable to reasonably estimate the potential loss.

Related Party Transactions

• On June 10, 2025, the company entered into a securities purchase agreement for a private placement of Series D Convertible Preferred Stock and Series I common stock purchase warrants.
• The purchasers in this private placement included Carl Spana (CEO), Stephen T. Wills (CFO/COO), John K.A. Prendergast (Director and Chairperson), and Alan W. Dunton (Director).
• Carl Spana and Stephen T. Wills each acquired 1,500 shares of Series D Preferred Stock.
• John K.A. Prendergast and Alan W. Dunton each acquired 200 shares of Series D Preferred Stock.

Stakeholder Impact

• Shareholders: Significant dilution risk from outstanding convertible securities (838,142 shares). Potential for further dilution from future capital raises. Delisting from NYSE American to OTCQB Venture Market may reduce liquidity and market value. The 'going concern' warning indicates substantial risk to investment.
• Employees: Employment agreements for key executives (CEO, CFO/COO) extended through June 30, 2028, providing stability for management. However, overall financial instability and potential need for cost reductions could impact other employees.
• Customers/Patients: Continued development of pipeline products (obesity, dry eye, ulcerative colitis, diabetic nephropathy) could lead to new treatment options. The sale of Vyleesi to Cosette means its commercialization is now dependent on Cosette.
• Partners (Boehringer Ingelheim, Cosette): The collaboration with Boehringer Ingelheim is a positive development, potentially leading to significant milestone payments and royalties. The settlement with Cosette resolves past obligations but limits future Vyleesi-related milestone payments.
• Creditors: The 'going concern' warning and low cash balance relative to current liabilities indicate increased credit risk.

Next Steps

• Obtain additional financing (equity, debt, or licensing) to fund operations and clinical trials.
• Complete required clinical trials for MC1R and MC4R product candidates.
• Complete submission of required regulatory applications to the FDA for successful product candidates.
• Advance IND-enabling activities for novel MC4R selective long-acting agonist and PL7737 oral small molecule MC4R agonist, with IND filings projected in Q1 2026.
• Initiate second Phase 3 clinical trial for PL9643 for dry eye disease, targeted for H1 2026.
• Vigorously defend against the lawsuit filed by H.C. Wainwright & Co., LLC.
• Resolve NYSE American listing deficiencies prior to the appeal hearing in late September 2025.
• Continue collaborative research with Boehringer Ingelheim for retinal diseases.

Key Dates

Recommendation

The company faces severe financial challenges, including a substantial accumulated deficit, ongoing net losses, and a 'going concern' warning from management and auditors. The delisting from NYSE American to the OTCQB Venture Market significantly reduces liquidity and investor confidence. While the Boehringer Ingelheim collaboration and positive pipeline data offer long-term potential, the immediate financial instability and the explicit need for substantial additional funding on uncertain terms present a very high risk profile. The current cash position is insufficient to cover current liabilities, and the company may be forced to curtail operations or cease entirely if funding is not secured. This combination of factors points to a strong negative outlook for the stock in the near to medium term.

Keywords

Biopharmaceutical, Melanocortin Receptor System, MC4R Agonists, Obesity Treatment, Dry Eye Disease, Ulcerative Colitis, Diabetic Nephropathy, Drug Development, Clinical Trials, SEC Filing, Going Concern, Boehringer Ingelheim, Cosette Pharmaceuticals, Vyleesi, PL9643, PL8177, Bremelanotide, Tirzepatide, Biotechnology, Pharmaceuticals, Financial Reporting, Risk Factors, NYSE American Delisting, OTCQB Venture Market, Intellectual Property, Capital Raise